What one share of DiaMedica Therapeutics holds
We are a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from severe ischemic disease with two main clinical programs focused on preeclampsia (PE) / fetal growth restriction (FGR) and acute ischemic stroke (AIS).
DiaMedica Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.72 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.60 |
| Cash and investments | $0.81 |
| Book value | $0.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$0.72 | $0.00 | −$0.66 | — | $0.13 |
| 2018 | $0.06 | −$0.74 | $0.01 | −$0.74 | — | $1.42 |
| 2019 | — | −$0.89 | $0.00 | −$0.76 | — | $0.63 |
| 2020 | — | −$0.78 | $0.00 | −$0.59 | — | $1.39 |
| 2021 | — | −$0.65 | $0.00 | −$0.59 | — | $1.66 |
| 2022 | — | −$0.52 | $0.00 | −$0.44 | — | $1.20 |
| 2023 | — | −$0.60 | $0.00 | −$0.58 | — | $1.35 |
| 2024 | — | −$0.60 | $0.00 | −$0.55 | — | $0.95 |
| 2025 | — | −$0.70 | $0.00 | −$0.62 | — | $1.04 |
Common questions about DiaMedica Therapeutics
How much does one share of DiaMedica Therapeutics earn?
Over the last 12 months, DiaMedica Therapeutics lost $0.72 for each share.
Does DiaMedica Therapeutics pay a dividend?
DiaMedica Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is DiaMedica Therapeutics’s book value per share?
DiaMedica Therapeutics’s book value is $0.71 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of DiaMedica Therapeutics have?
Each share of DiaMedica Therapeutics has $0.81 of cash and investments, as of June 30, 2026.
What is DiaMedica Therapeutics’s free cash flow per share?
−$0.60 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has DiaMedica Therapeutics bought back shares?
DiaMedica Therapeutics’s share count rose about 691% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.